Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim
Chun-Rong Chen, … , Basil Rapoport, Sandra M. McLachlan
Chun-Rong Chen, … , Basil Rapoport, Sandra M. McLachlan
Published June 15, 2003
Citation Information: J Clin Invest. 2003;111(12):1897-1904. https://doi.org/10.1172/JCI17069.
View: Text | PDF
Article Autoimmunity

The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim

  • Text
  • PDF
Abstract

Graves disease, a common organ-specific autoimmune disease affecting humans, differs from all other autoimmune diseases in being associated with target organ hyperfunction rather than organ damage. Clinical thyrotoxicosis is directly caused by autoantibodies that activate the thyrotropin receptor (TSHR). The etiology of Graves disease is multifactorial, with nongenetic factors playing an important role. Of the latter, there is the intriguing possibility that the molecular structure of the target antigen contributes to the development of thyroid-stimulatory autoantibodies (TSAb’s). Among the glycoprotein hormone receptors, only the TSHR undergoes intramolecular cleavage into disulfide-linked subunits with consequent shedding of some of the extracellular, autoantibody-binding A subunits. Functional autoantibodies do not arise to the noncleaving glycoprotein hormone receptors. Recently, TSAb’s were found to preferentially recognize shed, rather than attached, A subunits. Here we use a new adenovirus-mediated animal model of Graves disease to show that goiter and hyperthyroidism occur to a much greater extent when the adenovirus expresses the free A subunit as opposed to a genetically modified TSHR that cleaves minimally into subunits. These data show that shed A subunits induce or amplify the immune response leading to hyperthyroidism and provide new insight into the etiology of Graves disease.

Authors

Chun-Rong Chen, Pavel Pichurin, Yuji Nagayama, Francesco Latrofa, Basil Rapoport, Sandra M. McLachlan

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
TSHR Ab’s measured by ELISA in mice immunized with TSHR-adenovirus. BALB...
TSHR Ab’s measured by ELISA in mice immunized with TSHR-adenovirus. BALB/c mice were injected intramuscularly with adenovirus expressing the shed A subunit (TSHR-289), the noncleaving receptor (TSHR-D1NET), the WT TSHR (TSHR-WT), or control adenovirus (Con). Ab binding to TSHR protein–coated ELISA wells was tested in sera diluted 1:103 for mice immunized with TSHR-adenovirus and in sera diluted 1:102 for mice injected with control adenovirus. Data shown are the OD values for individual mice in experiment 1 (a) and experiment 2 (b), with the number of animals in each group in parentheses. The gray area indicates the mean ± 2 SD of values for ten control adenovirus-immunized mice.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts